Search

Your search keyword '"Straaten, R.J.H.M. van der"' showing total 4 results
Start Over Author "Straaten, R.J.H.M. van der"
4 results on '"Straaten, R.J.H.M. van der"'

1. Insulin-like growth factor 1 receptor expression and polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial (BOOG 2010-01)

Author

Groot, S. de, Charehbili, A., Laarhoven, H.W.M. van, Mooyaart, A.L., Dekker-Ensink, N.G., Ven, S. van de, Janssen, L.G.M., Swen, J.J., Smit, V.T.H.B.M., Heijns, J.B., Kessels, L.W., Straaten, R.J.H.M. van der, Bhringer, S., Gelderblom, A.J., Hoeven, J.J.M. van der, Guchelaar, H.J., Pijl, H., and Kroep, J.R.

Published
2016

4. Refining EGFR-monoclonal antibody treatment in colorectal cancer

Author

Krens, L.L., Guchelaar, H.-J., Gelderblom, A.J., Straaten, R.J.H.M. van der, and Leiden University

Subjects
FCGR3A, Metastatic colorectal cancer, Organ dysfuction, Panitumumab, EGFR-antibodies, KRAS, Cetuximab, neoplasms, digestive system diseases
Abstract

The use of the epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab is limited to colorectal cancer (CRC) patients with KRAS wild type tumors and more recently in RAS wild type only. After having become chemotherapy refractory, treatment options are limited for this substantial patient group. This means that there is an urgent need to optimize anti-EGFR therapy. The work presented in this thesis aimed at optimising EGFR targeted monoclonal antibody therapy in metastatic CRC. This thesis investigates several strategies to refine EGFR targeted monoclonal antibody therapy in CRC by: 1. statins and their ability to phenoconvert KRAS mutant CRC; __ 2. exploration of polymorphisms in the gene encoding FCGR3A and their association __with cetuximab efficacy; __ 3. and investigating the pharmacokinetics of cetuximab and panitumumab in patients with renal or hepatic dysfunction. __

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results